Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3656 | Replenish protein group Wiki | 0.71 |
| drug4123 | Standard protein group Wiki | 0.71 |
| drug2895 | Nutritional assessment Wiki | 0.71 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 2 clinical trials
The investigator will investigate the effect of supplemental enteral protein (1.2 g/kg/day) added to standard formula to achieve high amount of enteral protein (range 2-2.4 g/kg/day) given from ICU day 5 until ICU discharge up to ICU day 90 as compared to no supplemental enteral protein to achieve moderate amount enteral protein (0.8-1.2 g/kg/day), given in conjunction with similar amounts of stepwise caloric administration in the two groups on all-cause 90-day mortality.
Description: Mortality 90 days post randomization
Measure: 90 day-all cause mortality Time: 90 daysDescription: use of vasopressor/inotropic support, invasive mechanical ventilation and/or renal replacement therapy
Measure: Days alive at day 90 without life support Time: 90 daysDescription: 90 day survival after randomization
Measure: Days alive and out of hospital at day 90 Time: 90 daysDescription: Any symptoms of bacteremia
Measure: Bacteremia until 2 days of ICU stay Time: until 2 days post ICU.Description: anytime during ICU stay
Measure: New or progression of Skin Pressure Ulcers Time: ICU stayDescription: SARC-F screen for sarcopenia and EuroQoL
Measure: Functional assessment at day 90 Time: Day 90Description: New episode of stage 2 or higher AKI by KDIGO criteria; 2. Pneumonia defined as episodes of newly confirmed pneumonia according to the modified CDC criteria; 3. Grade IV Acute Gastrointestinal injury (AGI)
Measure: Safety outcomes during ICU stay Time: ICU stayDescription: Feeding tolerance; Diarrhoea; Refeeding syndrome
Measure: Minor safety outcomes during ICU stay Time: ICU stayThe nutritional consequences of the infection by the SARS-CoV-2 are as follows: - A severe respiratory infection induces an inflammatory syndrome and hypercatabolism, as well as an increase in energy expenditure related to ventilatory work; nutritional requirements (calories and protein) are therefore increased. - Food intake is often reduced by several factors: anorexia secondary to infection, respiratory discomfort, anosmia, ageusia, obesity, stress, confinement, organizational problems limiting meal assistance. Then, it is important to asses the nutritional status of COVID patients hospitalized in conventional COVID units (excluding intensive care).
Description: The nutritional status of patients within the first 72 hours after hospital admission will be categorized according to the French Haute Authorité de Santé (France, 2019) non-malnourished patient moderately malnourished patient severely malnourished patient
Measure: Nutritional status of COVID infected patients Time: Up to 72 hoursDescription: The supplemental oxygen requirement classified as follows: non-severe: no need of Oxygen light: 1 - 2 l/min moderate: 3 - 5 l/min severe: > 5 l/min critical: mechanical ventilation
Measure: Correlation between the nutritional status and the supplemental oxygen requirement Time: Up to 72 hoursDescription: The prognostic after hospitalization will be classified as follows: Hospital discharge Transfer to the intensive care unit Transfer to other unit Follow-up care and rehabilitation Death
Measure: Correlation between the nutritional status and the prognostic after hospitalization Time: Up to 72 hoursAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports